Advanced Utilization Management Program
National CooperativeRx constantly monitors the pharmaceutical marketplace for new therapies in the pipeline. We have implemented our opt-in Advanced Utilization Management program to offer our member groups an opportunity to employ our recommendations on a quarterly basis to better adapt their plans to the rapidly changing market. We are currently focusing on the management of the following categories.
Antichelation Medications for Wilsons’s Disease or cystinuria (Cuprimine, Depen only)
Target Drugs: trientine, Syprine, Clovique, Cuprimine, Depen
Target Drug: Prevymis
Continuous Blood Glucose Monitors (CGM), where covered
Target Drugs: Dexcom Receiver
Target Drug: Sucraid
New-to-Market Anti-Seizure Nasal Sprays (e.g. seizure rescue medications)
Target Drugs: Valtoco, Nayzliam
Oral Allergy Immunotherapy, where covered
Target Drugs: Grastek, Odactra, Oralair, Ragwitek, Palforzia
Target Drugs: Nurtec, Ubrelvy, Reyvow
Target Drugs: Sunosi, Xyrem
This page was last updated on April 23, 2021.